Levesialle Diario (Ethinylestradiol, Levonorgestrel | Lactose)

Ethinylestradiol supplies estrogenic feedback that suppresses the mid‑cycle surge of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). Levonorgestrel, a progestogen, reinforces this suppression, prevents follicular development, thickens cervical mucus, and induces endometrial changes that are unfavorable for implantation.

The specific dosing regimen is determined by the prescribing healthcare professional. Typically, the medication is taken as one tablet daily at the same time each day, but the exact schedule and duration are set by the prescriber based on individual needs.

Levesialle Diario is contraindicated during pregnancy and should not be started by a woman who is pregnant or suspects pregnancy. While limited data exist for breastfeeding, the product is generally not recommended unless the benefits outweigh potential risks; a healthcare provider should be consulted.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Levesialle Diario contains the classic ethinylestradiol‑levonorgestrel combination, which is widely used and well‑studied. Compared with newer formulations that include drospirenone or desogestrel, it offers similar contraceptive efficacy but may have a different side‑effect profile, such as a slightly higher risk of weight gain and less impact on acne.

Store the tablets at room temperature below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight. Do not use tablets that are discolored, broken or past the expiration date.

Levesialle Diario is taken orally as a tablet, usually with a glass of water. It should be taken at the same time each day, without crushing or chewing, to maintain consistent hormone levels and effectiveness.

Serious risks include venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism, arterial events like stroke or myocardial infarction, and severe allergic reactions. Women with a history of clotting disorders, smoking heavily, or with certain cardiovascular conditions should be closely monitored or avoid use.

Levesialle Diario is contraindicated for women who are pregnant, breastfeeding (unless advised by a physician), have a history of thromboembolic disease, uncontrolled hypertension, active liver disease, known or suspected hormone‑dependent tumors, or who smoke more than 15 cigarettes per day.